Biomarker development for myasthenia gravis
暂无分享,去创建一个
R. Conwit | G. Cutter | I. Aban | G. Wolfe | H. Kaminski | L. Kusner | G. Minisman
[1] R. Mantegazza,et al. A New Thiopurine S‐Methyltransferase Haplotype Associated With Intolerance to Azathioprine , 2013, Journal of clinical pharmacology.
[2] M. Benatar,et al. Recommendations for myasthenia gravis clinical trials , 2012, Muscle & nerve.
[3] R. Conwit,et al. Implementing clinical trials on an international platform: Challenges and perspectives , 2012, Journal of the Neurological Sciences.
[4] Kimberly Scearce-Levie,et al. Animal Models of Alzheimer's Disease: Modeling Targets, Not Disease Accelerating Drug Discovery for Alzheimer's Disease: Best Practices for Preclinical Animal Studies , 2022 .
[5] P. Christadoss,et al. Complement and cytokine based therapeutic strategies in myasthenia gravis. , 2011, Journal of autoimmunity.
[6] S. H. van der Burg,et al. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers , 2011, Clinical Cancer Research.
[7] D. Cacchiarelli,et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy , 2011, EMBO molecular medicine.
[8] D. Sanders,et al. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. , 2010, Current opinion in neurology.
[9] A. Vincent,et al. Autoimmune Channelopathies: Well-Established and Emerging Immunotherapy-Responsive Diseases of the Peripheral and Central Nervous Systems , 2010, Journal of Clinical Immunology.
[10] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[11] V. Bajic,et al. A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis , 2009, Genes and Immunity.
[12] Weidong Zhou,et al. Core-Shell Hydrogel Particles Harvest, Concentrate and Preserve Labile Low Abundance Biomarkers , 2009, PloS one.
[13] D. Richman,et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis , 2008, Neurology.
[14] A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis , 2008, Neurology.
[15] R. Conwit,et al. Status of the Thymectomy Trial for Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone , 2008, Annals of the New York Academy of Sciences.
[16] I. Kola,et al. The State of Innovation in Drug Development , 2008, Clinical pharmacology and therapeutics.
[17] R. Weinshilboum,et al. Metabolomics: a global biochemical approach to drug response and disease. , 2008, Annual review of pharmacology and toxicology.
[18] H. Kaminski,et al. Effect of complement and its regulation on myasthenia gravis pathogenesis , 2008, Expert review of clinical immunology.
[19] J. Mendell,et al. Challenges in drug development for muscle disease: A stakeholders' meeting , 2007, Muscle & nerve.
[20] Monica Milani,et al. Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.
[21] Alex Matter,et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.
[22] R. Barohn,et al. Myasthenia gravis , 2000, Neurology.
[23] D B Sanders,et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. , 2000, Neurology.
[24] P. Christadoss,et al. Animal models of myasthenia gravis. , 2000, Clinical immunology.
[25] John Newsom-Davis,et al. A randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravis , 1998, Neurology.
[26] V. Lennon. Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome , 1997, Neurology.
[27] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[28] L. Elveback,et al. Clinical Correlations of Antibodies That Bind, Block, or Modulate Human Acetylcholine Receptors in Myasthenia Gravis a , 1987, Annals of the New York Academy of Sciences.
[29] J. Patrick,et al. Autoimmune Response to Acetylcholine Receptor , 1973, Science.
[30] L. Phillips,et al. Epidemiology and Genetics of Myasthenia Gravis , 2009 .
[31] D. Sanders. Chapter 18 Electrophysiologic tests of neuromuscular transmission , 2004 .
[32] D. Sanders. Electrophysiologic tests of neuromuscular transmission. , 2004, Supplements to Clinical neurophysiology.
[33] S. Hanash. Disease proteomics : Proteomics , 2003 .
[34] S. Hanash,et al. Disease proteomics , 2003, Nature.